Abstract
BillionToOne, Inc. will report its second-quarter 2026 results on August 5, 2026 Post Market, with the market watching revenue stability around the 100 million US dollars level, margin resilience, and updates on prenatal and oncology growth vectors.
Market Forecast
Consensus for the current quarter centers on revenue of 109.37 million US dollars, adjusted EPS of 0.18, and EBIT of 10.07 million US dollars; year-over-year comparisons were not provided, and management has not indicated a quarterly gross margin or net margin target. The company’s prior report raised full-year 2026 revenue guidance to a range of 450.00–465.00 million US dollars, implying continued momentum through the midyear period even as quarterly revenue growth moderates sequentially.
The main business, prenatal screening, remains the anchor with the prior-quarter mix at 96.53 million US dollars (about 89% of revenue) and is expected to remain the core revenue and profit contributor as payer coverage broadens and average selling prices remain firm. The most promising segment is oncology, which contributed 10.72 million US dollars last quarter and grew more than 300% year over year on the back of early adoption; continued product expansion and clinical leadership hires are poised to extend this trajectory, albeit off a small base.
Last Quarter Review
BillionToOne, Inc. delivered 108.39 million US dollars in revenue, a 72.97% gross profit margin, GAAP net profit attributable to shareholders of 17.97 million US dollars, a 16.58% net profit margin, and adjusted EPS of 0.34 in the previous quarter, with year-over-year comparisons for EPS and total revenue not disclosed.
A key financial highlight was the sharp profitability inflection: net profit rose 610% quarter-on-quarter, supported by an operating profit of 17.83 million US dollars and strong unit economics, while gross margin expanded meaningfully compared with the prior year period. Operationally, prenatal products generated 96.53 million US dollars and oncology 10.72 million US dollars, with oncology revenue up over 300% year over year and prenatal revenue up about 72% year over year; deliveries reached 187,823 tests as average selling prices climbed to 571 US dollars, underscoring improved mix and reimbursement.
Current Quarter Outlook (with major analytical insights)
Core Prenatal Screening Business
The prenatal screening franchise remains the principal driver of the P&L this quarter. With last quarter revenue of 96.53 million US dollars and gross margins near 73%, this segment provides the scale and profitability that anchor overall results. Contracting momentum continues to offer volume and pricing support, highlighted by the recent in‑network status with Anthem that expands covered lives to roughly 300 million. That contracting breadth tends to reduce out-of-network frictions, improve cash collection predictability, and support higher realized pricing, which was already evident in last quarter’s 28% year-over-year increase in average selling price to 571 US dollars per test.
This quarter, the key watch points inside prenatal are volume progression, mix, and realized reimbursement. Based on the company’s raised full-year outlook and the consensus revenue estimate of 109.37 million US dollars, prenatal is likely to sustain high utilization rates, though sequential revenue growth at the corporate level is modest at about 0.90%. Mix can skew richer if newer confirmatory offerings such as Unity Confirm scale usage within existing provider networks; if that occurs, gross margin can remain in the low-70s range even as volume grows. Conversely, any softening in commercial payer processing times or a shift toward lower-priced plans could delay cash conversion and compress margin, so commentary on collections and days sales outstanding will be material to how the market reads the sustainability of margin strength.
The second notable determinant for prenatal is ASP stability. Last quarter’s ASP uplift was driven by improved payer coverage and product mix; with expanded in‑network coverage and more comprehensive test menus, ASP should remain stable to slightly up on a year-over-year basis. Management color on authorization rates and denials will help investors calibrate whether the current pricing holds. The consensus EBIT expectation of 10.07 million US dollars suggests the Street anticipates slightly lower operating leverage sequentially, which could reflect cautious assumptions on operating expenses tied to commercial expansion and product development.
High-Potential Oncology Franchise (Northstar)
Oncology is the most promising growth vector and the piece of the story where incremental news flow may matter most for sentiment. Revenue rose to 10.72 million US dollars last quarter, more than quadrupling year over year from a small base, as the company accelerated adoption of its Northstar platform and related assays. The recent appointment of Dr. Ethan Dmitrovsky as Chief Medical Officer of Oncology adds clinical leadership focus that can translate to more robust medical affairs engagement, clearer evidence-generation pathways, and potentially faster inclusion in clinical practice patterns.
What matters this quarter is not the absolute oncology revenue contribution—still less than 10% of total—but the trajectory signals. Early adopter sites, initial payor coverage positions, and the pace of clinical study enrollment or readouts will indicate whether this ramp can continue at a high double-digit pace sequentially or if growth normalizes temporarily as pilots expand to broader usage. Given the high gross margin profile for precision assays, every incremental oncology dollar has an outsized impact on consolidated profitability. If management reiterates an expanding academic center footprint and improving pull-through per account, investors may extrapolate continued triple-digit year-over-year growth for several quarters, recognizing that quarterly progress can be lumpy as new accounts onboard and validate workflows.
Looking beyond the quarter, oncology’s catalyst path includes deepening MRD use cases and broadening into adjacent tumor types or clinical contexts via the Northstar platform. Clarity on health economic outcomes, coding and reimbursement progress, and real-world utilization rates can lower perceived adoption risk. Commentary on study timelines and interim data milestones may influence how the market prices the medium-term revenue curve. In the near term, even modest absolute upside from oncology can disproportionately reinforce the company’s multi-segment margin profile if prenatal margin remains resilient.
Stock Price Drivers This Quarter
Margin quality and revenue mix will likely be the core stock drivers around the print. Investors will focus on whether gross margin holds near the low-70s percentage after its significant improvement last quarter; resilience would validate pricing discipline and payor coverage traction, while any downtick would prompt debate on mix or pricing. With consensus revenue at 109.37 million US dollars and EPS at 0.18, small deviations in ASP or unit volumes can generate visible EPS variance given the company’s fixed-cost structure and the sensitivity of gross profit dollars at current scale. The Street’s implied EBIT step-down from 17.83 million US dollars actual to the 10.07 million US dollars estimate embeds conservatism on spending or margin normalization; better-than-expected opex discipline or stronger-than-modeled prenatal volumes could drive an upside surprise.
Guidance will be an equally important catalyst. The company raised its full-year revenue outlook to 450.00–465.00 million US dollars after last quarter’s beat; markets will parse whether that range is reaffirmed or refined and whether the quarter keeps run-rate revenue consistent with mid-range achievement. Given the small quarter-on-quarter revenue delta implied by consensus (about 0.90%), investors may treat updated color on the second-half pipeline and contracting tailwinds as the determinant of whether the full-year guide remains conservative. Additionally, cash-flow commentary and working capital cadence—especially collections from expanded payer networks—will shape views on the durability of earnings power and the capital available for R&D and commercial investments without diluting margins.
Operational updates can provide added volatility. Management’s discussion of Unity Confirm adoption trends and the conversion of newly contracted payors into active claims inflows will help benchmark volume momentum. On oncology, clarity on clinical collaborations, early MRD traction, and plans under the new oncology CMO should give the market a read on how quickly that business can scale. Any signal that oncology can sustain high triple-digit year-over-year growth while maintaining high gross margin would reinforce the multi-year expansion case, even if near-term contribution to total revenue remains modest.
Analyst Opinions
Across the latest collected views, the balance of opinion is bullish. Recent rating actions include Buy reiterations from J.P. Morgan (analyst Casey Woodring, 145.00 US dollars target), Stifel Nicolaus (analyst Daniel Arias, 145.00 US dollars target), and Guggenheim (analyst Subbu Nambi, 120.00 US dollars target). Separate commentary indicates seven institutions average a target price of 117.71 US dollars, consistent with an overall positive stance. One data point in the period highlighted a target-price trim by another firm without an accompanying downgrade, reflecting caution rather than a broad bearish turn. Based on these items, the bullish-to-bearish ratio stands at approximately 3:1, and the majority view is constructive on the shares into the print.
Proponents of the bullish view cite four factors. First, prenatal screening’s high and stable gross margin combined with expanded in‑network coverage continues to underpin consolidated profitability, reducing downside risk to earnings as volumes scale. Second, the oncology franchise is growing rapidly off a low base, with more than 300% year-over-year revenue growth last quarter; its contribution to margin should increase as adoption broadens, yielding positive mix over time. Third, the raised full-year revenue outlook of 450.00–465.00 million US dollars following the prior-quarter beat increases confidence that the company can deliver above the initial trajectory for 2026. Fourth, management’s commercial execution—evidenced by ASP uplift, deeper payer penetration, and evidence-building under newly strengthened clinical leadership—supports a multi-quarter runway for both revenue and margin expansion.
In their framing, Buy-rated analysts see this quarter’s setup as balanced on revenue but skewed positively on execution signals. With consensus revenue at 109.37 million US dollars and EPS at 0.18, stability in gross margin near the low-70s percentage and reaffirmation of full-year guidance could be sufficient to maintain or improve sentiment. Upside could come from stronger prenatal volumes or a faster-than-expected oncology ramp, each carrying attractive incremental margins. Conversely, analysts acknowledge that any reversal in ASP trends or delays in payer collections could compress near-term results; however, they generally view contract momentum and product mix as supportive. The emphasis remains on management color around coverage conversion and oncology adoption pace to validate that the raised full-year guide remains achievable with room to spare.
The bullish camp also underscores improving earnings quality. Last quarter’s swing to a 17.97 million US dollars GAAP net profit with a 16.58% net margin demonstrates that scale economics are taking hold, and the Street’s more conservative EBIT expectation of 10.07 million US dollars this quarter leaves room for positive variance if opex growth is paced prudently. Analysts expect the company to continue prioritizing high-return commercial spend while leveraging operating efficiencies from larger test volumes. They argue that as oncology grows and prenatal maintains coverage-driven ASP support, blended margins should track higher than those of peers focused on lower-priced, less differentiated testing offerings, thus supporting a premium valuation framework despite near-term multiples that may screen elevated.
In sum, the majority view anticipates a steady quarter with near-term financials roughly in line but with multiple incremental proof points—coverage conversion, high-70s gross profit per incremental test, and oncology adoption markers—that can reinforce the longer-term expansion story. Should management reiterate the 450.00–465.00 million US dollars full-year revenue guide and provide confident commentary on prenatal and oncology execution, bullish analysts expect the stock’s narrative to remain intact, with subsequent quarters offering greater room for upside as new accounts ramp and evidence generation advances.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments